Are you curious about the latest advancements in AI-enabled antibody discovery? In this podcast series, we dive into the world of Antiverse - we are accelerating drug discovery against difficult targets, including GPCRs and ion channels, using machine learning and phage display techniques.
Join us as we discuss our mission to target cancer, cardiovascular disease, and other challenging conditions. Discover how we leverage AI and wet lab innovation to accelerate the discovery and development of biologics. Plus, learn about our unique approach to antibody discovery, our progress with our internal pipeline of antibodies against GPCRs and other challenging targets, as well as our exciting ongoing collaborations. Tune in and join us at the forefront of antibody discovery!
Things mentioned:
Murat Tunaboylu, Co-Founder and CEO of Antiverse.
Twist Bioscience, a Synthetic Biology company that develops and manufactures synthetic DNA.
Antiverse, an AI-first biologics discovery company that designs antibodies against difficult -to-drug targets.
Watch the full presentation, with slides! https://youtu.be/cRHxi4MWExQ
Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.
Podden och tillhörande omslagsbild på den här sidan tillhör Murat Tunaboylu. Innehållet i podden är skapat av Murat Tunaboylu och inte av, eller tillsammans med, Poddtoppen.
